Drug Profile
Beta-L-FddC
Alternative Names: 5-F-b-L-ddC; 5-F-beta-L-ddCLatest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Nonindustrial source; Shire Pharmaceuticals Group; Vion Pharmaceuticals
- Class
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B; HIV infections
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 05 Jun 2001 BioChem Pharma has been acquired by Shire Pharmaceuticals Group
- 18 Dec 1998 Preclinical development for HIV infections treatment in USA (Unknown route)